GIM
EVH icon

Glenmede Investment Management’s Evolent Health EVH Stock Holding History

Glenmede Investment Management’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$10.5M Buy
1,238,477
+160,164
+15% +$1.55M 0.05% 341
2025
Q2 		$12.1M Buy
+1,078,313
New +$9.9M 0.06% 310

Other funds holding EVH

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Glenmede Investment Management's EVH Position: Q3 2025 in Review

Glenmede Investment Management increased its Evolent Health (EVH) stake by 15% in Q3 2025, buying an estimated $1.55M and bringing the position to 1,238,477 shares worth $10.5M. The position accounts for 0.05% of the portfolio, ranked #341.

Glenmede Investment Management first reported a position in EVH in Q2 2025 and has held it in 2 quarters since. The position peaked at $12.1M in Q2 2025. 240 funds tracked by Wall St. Rank hold EVH as of Q3 2025.

  • Glenmede Investment Management held 1,238,477 shares of Evolent Health worth $10.5M as of Q3 2025.
  • Glenmede Investment Management bought 160,164 Evolent Health shares in Q3 2025, an estimated $1.55M.
  • Evolent Health made up 0.05% of Glenmede Investment Management's portfolio in Q3 2025, its #341 holding.
  • Glenmede Investment Management first reported a position in Evolent Health in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's Evolent Health position peaked at $12.1M in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Evolent Health as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.